MYC and Thrombocytopenia: However, despite reaching clinical trials over the past decade, BETi have not achieved regulatory approval due to dose-limiting toxicities such as thrombocytopenia and pulmonary arterial hypertension, combined with unclear trial data regarding their efficacy and mechanism of action in the context of MYC modulation (Whitfield and Soucek, 2025).